Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Long-term cohort studies

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background and objective Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. We studied whether Aβ 38 levels in CSF relate to risk of AD dementia and cognitive decline. Methods CSF Aβ 38 levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer's Disease Neuroimaging Initiative (ADNI).

What this study adds

Evidence grade: Moderate

This is a trial of 656 participants. This study examined whether cerebrospinal fluid levels of a short amyloid-beta species relate to risk of Alzheimer's disease dementia and cognitive decline. It was based on experimental evidence that the balance between short and long amyloid-beta species might affect amyloid-beta toxicity.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson-Carlgren, N., Hansson, O., et al. (2022). Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline. Neurology. https://doi.org/10.1212/wnl.0000000000013228

Vancouver

Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O, et al. Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline. Neurology. 2022. doi:10.1212/wnl.0000000000013228. PMID: 34937781.

BibTeX

@article{cullen2022-34937781,
  author  = {Cullen, N. and Janelidze, S. and Palmqvist, S. and Stomrud, E. and Mattsson-Carlgren, N. and Hansson, O. and {Alzheimer’s Disease Neuroimaging Initiative}},
  title   = {{Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline}},
  journal = {Neurology},
  year    = {2022},
  doi     = {10.1212/wnl.0000000000013228},
  pmid    = {34937781},
  url     = {https://doi.org/10.1212/wnl.0000000000013228}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study examined whether cerebrospinal fluid levels of a short amyloid-beta species relate to risk of Alzheimer's disease dementia and cognitive decline. It was based on experimental evidence that the balance between short and long amyloid-beta species might affect amyloid-beta toxicity.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 53 of the 96 points it could be judged on, which is 55 of 100. Total 55 of 100.53 of the 96 points we could judge = 55 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 53 of the 96 points we could judge it on, which is 55 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 2 / 4 656 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 43 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.2 citations a year over 6 year(s) since 2022
Impact for its field and year 3 / 6 Cited 5.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 1 / 3 Lund University: institution h-index 1,119 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34937781)
Free to read 2 / 2 Free to read
Points 53 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 96 points we could judge it on is 55 out of 100.
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →